Atyr PHARMA (NASDAQ:ATYR – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.
Institutional and Insider Ownership
61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Atyr PHARMA and Caribou Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atyr PHARMA | $350,000.00 | 925.74 | -$50.39 million | ($0.94) | -4.11 |
| Caribou Biosciences | $34.48 million | 3.76 | -$102.07 million | ($1.65) | -0.87 |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Atyr PHARMA and Caribou Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atyr PHARMA | 0 | 0 | 5 | 0 | 3.00 |
| Caribou Biosciences | 0 | 0 | 5 | 0 | 3.00 |
Atyr PHARMA presently has a consensus price target of $19.25, suggesting a potential upside of 398.70%. Caribou Biosciences has a consensus price target of $10.33, suggesting a potential upside of 622.61%. Given Caribou Biosciences’ higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Atyr PHARMA.
Profitability
This table compares Atyr PHARMA and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atyr PHARMA | N/A | -79.44% | -59.16% |
| Caribou Biosciences | -1,290.81% | -45.46% | -38.07% |
Risk & Volatility
Atyr PHARMA has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.
Summary
Caribou Biosciences beats Atyr PHARMA on 8 of the 12 factors compared between the two stocks.
About Atyr PHARMA
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.
